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In Response: Vitzthum and Thornburg’s comments seem to reflect a basic 
misunderstanding of our paper and its results. As noted in the title of the article, we 
document an association between CYP17 genotypes and salivary estradiol levels. 
Variation in follicular steroidogenesis, up to and including ovulatory failure, is precisely 
the variation we are studying. To remove anovulatory cycles from the sample would be to 
remove a principal source of variance in estradiol levels between women, a source of 
variation with direct implications for breast cancer risk (1).  
Vitzthum and Thornburg are also incorrect in their assertion that our statistical methods 
are flawed. In the repeated-measures ANOVA, the univariate F statistic may be safely 
used when accompanied by appropriate adjustments (Geisser-Greenhouse and Huynh-
Feldt) to the degrees of freedom (even if the sphericity requirement is not met). In the 
article, we provided P values obtained under both types of adjustment. Our use of the 
Wilcoxon signed-rank test adhered strictly to the assumptions specified in the principal 
textbook of biostatistical methods by Sokal and Rohlf (2).  
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